Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
165
-
Total 13F shares, excl. options
-
122M
-
Shares change
-
-6.96M
-
Total reported value, excl. options
-
$390M
-
Value change
-
-$22.1M
-
Put/Call ratio
-
6.14
-
Number of buys
-
85
-
Number of sells
-
-68
-
Price
-
$3.21
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2023
191 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q4 2023.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 165 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 122M shares
of 226M outstanding shares and own 53.72% of the company stock.
Largest 10 shareholders include FMR LLC (25.2M shares), TPG GP A, LLC (18.7M shares), BlackRock Inc. (10M shares), VANGUARD GROUP INC (9.03M shares), JPMORGAN CHASE & CO (6.91M shares), PRIMECAP MANAGEMENT CO/CA/ (5.28M shares), CITADEL ADVISORS LLC (4.05M shares), GOLDMAN SACHS GROUP INC (3.34M shares), Woodline Partners LP (2.58M shares), and STATE STREET CORP (2.43M shares).
This table shows the top 165 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.